You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 59 No. 1, January 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Neurotherapeutics
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (27)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology, Other
 •Alert me on articles by topic

Targeting Neurotherapeutic Agents Through the Blood-Brain Barrier

William M. Pardridge, MD

Arch Neurol. 2002;59:35-40.

The blood-brain barrier (BBB) is maintained by the endothelial tight junctions within the brain microvasculature. Most small-molecule neuropharmaceutical agents and virtually all large-molecule drugs do not cross the BBB. The BBB problem is the rate-limiting factor preventing the transfer of progress in the molecular neurosciences to the development of clinically effective neurotherapeutic agents. The future development of neurotherapeutic agents will be accelerated by the development of BBB drug-targeting technology.


From the Department of Medicine, University of California, Los Angeles, UCLA School of Medicine.


RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(1):155-157.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.